trial · primary record
Avelumab
Thymoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 56 |
| Primary completion | 2028-03-30 |
| Primary endpoint | Safety and tolerability of Avelumab based on NCI-CTCAE v4.0 |
| Registry ID | NCT03076554 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:31:44.781Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03076554
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.